2. Venture Investment Bank for Early Stage Technology Companies We Invest Through: –Angel & Institutional Investor Members –Capital Managed Internally NASD\Broker Dealer Who We Are

3. VCs Don’t Invest in Early Stage Companies Angels Do! The Fact is……

4. Seed‘A’ Round ‘B+’ Rounds Mezzanine IPO/Exit $200k $.5 – $5M $10M+ $10 - $30M $40M+ Capital Chasm Early Stage

5. 1.Get out 20 Envelopes Ten Highly Effective Habits of Successful Angel Investing

6. 2.Be Quick but don’t Hurry Ten Highly Effective Habits of Successful Angel Investing

7. 3.Invest in Deals you Understand Ten Highly Effective Habits of Successful Angel Investing

8. 4.Don’t try to change the Company Ten Highly Effective Habits of Successful Angel Investing

9. 5.Do your own Competitive Analysis Research Ten Highly Effective Habits of Successful Angel Investing

10. 6.Get to KNOW the Customer Ten Highly Effective Habits of Successful Angel Investing

11. 7.Really get to KNOW the Team Ten Highly Effective Habits of Successful Angel Investing

12. 8.Never, ever Fall in Love Ten Highly Effective Habits of Successful Angel Investing

13. 9.Know the Intellectual Property Ten Highly Effective Habits of Successful Angel Investing

14. 10.Know who you pass the Baton to – before you invest Ten Highly Effective Habits of Successful Angel Investing

15. Our Value Proposition is Superior Deal Selection & Superior Deal Support

16. Initial Screening by Angel Capital Staff Qualified Deals go to Expert Angel Members for Analysis Engage VCs in Due Diligence Review Engage Relevant Strategic Investors Deal Selection Process

17. Angel Investors with Deep Relevant Industry Experience Willing to: – Invest – Serve as Advisors VCs Willing to Fund Later Rounds Based on Certain Milestones Defensible IP Deal Selection Criteria

18. Introduce: –Expert Angels Who Invest and Join Board –Industry Board Members –Strategic Relationships –VCs with Relevant Expertise Valuation and Deal Structure Ongoing Corporate Finance Services Deal Support

19. Disruptive Technology in Intelligent Storage Networks 12 patents filed, more to come Market projected to grow 900% by 2003 to $6.7B Experienced management team has built two successful companies Elite industry board Key industry relationships in place

20. BioRight International, Inc. Breakthrough Nonprescription Cold & Allergy Medicines Launched 11/00 - Sales Exceeding $1.3 Million Distribution in Over 22,000 Retail Pharmacies – Walgreens, Rite-Aid, Eckerds, Safeway, Osco, Longs Pipeline for New Product Introductions Revenue Growth to Over $100 Million Within 5 Years Management Combines Medical Expertise With 25 Year Track Record of Retail Product Introductions

21. Multifocal Contact Lens With Strong Patents and High Consumer Demand Clinical Data Consistently Outperforms Any Lens on the Market (Including J&J Acuvue) FDA Approval Received for: –Custom (Lathed Lens) Launched in US and Canada –Cast Molded Lens (Disposable & Mass Produced) CE Mark Received for Astigmatic Intraocular Lens

22. Mike Pogue - President –(415) 289-4618 –mpogue@angelcapitalnetwork.com Contact Information